Caspofungin

Acute Monocytic Leukemia

Children's Oncology GroupSmall moleculePhase 3Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

13 Active assets in the Acute Monocytic Leukemia cohort.

Asset / Sponsor	Phase	Rating
Etoposide Stanford University	Phase 3	BBB
Cytarabine Chinese PLA General Hospital	Phase 3	BBB
Daunomycin National Cancer Institute (NCI)	Phase 3	BBB
Cyclophosphamide ECOG-ACRIN Cancer Research Group	Phase 3	BBB
Nivestim Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 3	BBB

View all 49 →

Same molecule, other indications

Caspofungin is also rated in:

fungal infectious diseaseDormant

BBB

Indicative · Phase 4

77 / 100

adult acute monocytic leukemiaDormant

BB

Indicative · Phase 3

64 / 100

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BB

Indicative · Phase 3

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.